NCT04872790 - Venetoclax, Dasatinib, Prednisone, Rituximab and Blinatumomab for the Treatment of Newly Diagnosed or Relapsed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia or Mixed Phenotype Acute Leukemia | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 2, 2022

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2026

Conditions

B Acute Lymphoblastic LeukemiaB Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1Mixed Phenotype Acute LeukemiaRecurrent B Acute Lymphoblastic LeukemiaRecurrent Mixed Phenotype Acute Leukemia

Interventions

DRUG

Dasatinib

Given PO

DRUG

Methotrexate

Given IT

DRUG

Prednisone

Given PO

BIOLOGICAL

Rituximab

Given IV

DRUG

Venetoclax

Given PO

BIOLOGICAL

Blinatumomab

Given IV

PROCEDURE

Bone Marrow Aspiration and Biopsy

Undergo bone marrow aspiration and biopsy

PROCEDURE

Lumbar Puncture

Undergo lumbar puncture

PROCEDURE

Biospecimen Collection

Undergo blood sample collection

Trial Locations (1)

97239

RECRUITING

OHSU Knight Cancer Institute, Portland